EPCAM and cancer: Catumaxomab, a hybrid mouse IgG2a/rat IgG2b antibody that is trispecific for EpCAM, CD3, and, via the Fcc receptor, that activates accessory cells such as macrophages, NK cells and DCs, obtained market approval in Europe in 2009 to treat malignant ascites in cancer patients.